A Phase I Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21 rIL-21) in Combination with Ipilimumab in Subjects with Unresectable Stage III or Stage IV Melanoma
-
- STATUS
- Not Recruiting
Summary
The purpose of this study is to test the safety and how patients with melanoma will tolerate an experimental drug called BMS-982470 together with another drug called ipilimumab that has been approved by the US Food and Drug Administration (FDA) for the tr
Description
The purpose of this study is to test the safety and how patients with melanoma will tolerate an experimental drug called BMS-982470 together with another drug called ipilimumab that has been approved by the US Food and Drug Administration (FDA) for the tr
Details
| Condition | Melanoma |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX2404 |
| Last Modified on | 19 February 2024 |
Similar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.